Skip to content

Georgia Panayiotou

2 papers in the library · 14 citations · publishing 2025-2026

Papers

Sort Most recent Most cited

Adjunctive ketamine for affective symptoms, craving, and relapse prevention in opioid use disorder: protocol for a randomised, double-blind, placebo-controlled clinical trial

BMC Psychiatry October 16, 2026 Morfeas Koumas, Markos Apostolakis, Evanthia Bella et al.

Abstract Background Opioid use disorder (OUD) is a chronic relapsing condition associated with substantial mortality. Although medications for opioid use disorder (MOUD) can be effective in reducing opioid use and improving treatment outcomes, relapse to drug use remains common, highlighting the need for adjunctive interventions that address relapse-relevant symptoms not fully targeted by MOUD...

Ketamine and Hydroxynorketamine as Novel Pharmacotherapies for the Treatment of Opioid Use Disorders.

Biological Psychiatry March 15, 2025 Anna Onisiforou, Andria Michael, Markos Apostolakis et al. 14 citations

Opioid use disorder (OUD) has reached epidemic proportions, with many countries facing high levels of opioid use and related fatalities. Although currently prescribed medications for OUD are considered lifesaving, they inadequately address negative affect and cognitive impairment, resulting in high relapse rates to nonmedical opioid use even years after drug cessation (protracted abstinence)....

DOI: 10.1016/j.biopsych.2024.09.008 (opens in new tab) Full text (opens in new tab) Hydroxynorketamine Opioid crisis Opioid use disorders Relapse +4